comprehensive -WSS

comprehensive

author：explore 2025-09-27 12:58:11 - browse：2383

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Trump indictment: Who are the 'co

focus

WSS

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Explaining an after

Humans aren't the only ones with an imagination. Rats have it too

Coloradans with cystic fibrosis could lose access to Trikafta

Amazon expands telehealth clinic nationwide

Explaining an after

Wikipedia

comprehensive

explore

Heart attack and stroke risk calculators need revising

Trump indictment: Who are the 'co

In age of alternative facts, a scholarly course on calling out crap

Pence says 'crackpot lawyers' told Trump what he wanted to hear

At least 13 dead in Texas as scorching temps continue

How to convince healthy people to buy insurance

Sports medicine is finally prioritizing gender equality

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Supreme Court strikes down use of affirmative action

Life sciences investors close nearly $6 billion in new funds

knowledge

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Explaining an after

Infectious disease expert Jeanne Marrazzo assumes Fauci role

New safety details link Apellis eye drug to rare cases of blindness

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Life sciences investors close nearly $6 billion in new funds

entertainment

leisure time

focus

knowledge